anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
US policy regarding media freedom was much more restrictive than in the Vietnam War. The policy had been spelled out in a Pentagon document entitled Annex Foxtrot. Most of the press information came from briefings organized by the military. Only selected journalists were allowed to visit the front lines or conduct interviews with soldiers. Those visits were always conducted in the presence of officers, and were subject to both prior approval by the military and censorship afterward. This was ostensibly to protect sensitive information from being revealed to Iraq. This policy was heavily influenced by the military's experience with the Vietnam War, in which public opposition within the US grew throughout the war's course. It was not only the limitation of information in the Middle East; media were also restricting what was shown about the war with more graphic depictions like Ken Jarecke's image of a burnt Iraqi soldier being pulled from the American AP wire whereas in Europe it was given extensive coverage. Two BBC journalists, John Simpson and Bob Simpson (no relation), defied their editors and remained in Baghdad to report on the war's progress. They were responsible for a report which included an "infamous cruise missile that travelled down a street and turned left at a traffic light." Alternative media outlets provided views opposing the war. Deep Dish Television compiled segments from independent producers in the US and abroad, and produced a 10-hour series that was distributed internationally, called The Gulf Crisis TV Project.
=== Bee–Ber === Lorena S. Beese(20th–21st century). Biochemist at Duke University, known for structural biochemistry of DNA replication and protein prenylation enzymes. Member Natl. Acad. Sci. USA. Helmut Beinert (1913–2007). German born-American biochemist at the University of Wisconsin–Madison, a pioneer of and advocate for the use of electron paramagnetic resonance in biological systems. Member Natl. Acad. Sci. USA. Marlene Belfort (b. 1945). American biochemist at the New York State Department of Health involved in the discovery of self-splicing introns in bacteriophage. Member Natl. Acad. Sci. USA. Boris Pavlovich Belousov (1893–1970). Chemist and biophysicist in the Ministry of Health of the USSR who discovered the Belousov–Zhabotinsky reaction. Awarded the Lenin Prize (1980). Myron L. Bender (1924–1988). American biochemist at Northwestern University, who pioneered mechanistic studies of enzymes, especially chymotrypsin and other proteases. Member Natl. Acad. Sci. USA. Stephen J. Benkovic (b. 1938). American bioorganic chemist at Pennsylvania State University. Member Natl. Acad. Sci. USA. Steven A. Benner (b. 1954). American chemist at the University of Florida known for establishing synthetic biology and paleogenetics, aas wll as contributing to understanding of the origin of life; Paul Berg FRS (foreign member) (1926–2023). American biochemist at Stanford, known for pioneering work involving gene splicing of recombinant DNA. He was awarded the Nobel Prize in Chemistry in 1980. Helen M. Berman (b. 1943).
This leads to a reduction in the newly synthesized pool of dopamine from replenished tyrosine. AMPT’s effect on dopamine concentration and transport is reversible and short-lived. If methamphetamine is administered while cytoplasmic dopamine is depleted to about 50% of the control levels, its neurotoxic effects are averted (Thomas et al., 2008). The recovery of dopamine to normal levels after AMPT administration takes about 2 to 7 days, and this repletion of dopamine is not changed by methamphetamine. For these reasons AMPT seems to be a better treatment drug in methamphetamine addicts than reserpine, which is also being researched as a possible methamphetamine treatment drug. Reserpine causes almost full loss of dopamine from the striatum by disrupting vesicle storage. The repletion of dopamine after reserpine administration is slower than AMPT. Additionally, administration of reserpine when dopamine is maximally depleted causes neurotoxic effects, which does not occur with AMPT treatment. AMPT’s role in addiction has also been studied via changes in dopamine binding to D2 and D3 receptors in the striatum (caudate, putamen, and ventral striatum) after the administration of AMPT. Findings revealed that cocaine-dependent subjects exhibited lower levels of endogenous dopamine relative to healthy subjects after AMPT administration. Similar positive effects were found in the role of AMPT in methamphetamine-addicted subjects. Dystonias and dyskinesias onset seems to derive from inconsistent regulation of dopamine in dopamine pathways.
Data from randomized controlled clinical trials indicate that the most common adverse reaction that was reported was injection site reactions. These reactions were mild and were present in 38 percent of patients treated with lumasiran. In 2022, the FDA and EMA approved vutrisiran for the treatment of adults with hereditary transthyretin mediated amyloidosis with polyneuropathy stage 1 or 2. Vutrisiran is designed to break down the mRNA that codes for transthyretin. Currently FDA-approved RNAi therapies are summarized below, along with their indicationsm, delivery strategies, and routes of administration.
==== Barth syndrome ==== Barth syndrome is a rare genetic disorder that was recognised in the 1970s to cause infantile death. It has a mutation in the gene coding for tafazzin, an enzyme involved in the biosynthesis of cardiolipin. Tafazzin is an indispensable enzyme to synthesize cardiolipin in eukaryotes involved in the remodeling of CL acyl chains by transferring linoleic acid from PC to monolysocardiolipin. Mutation of tafazzin would cause insufficient cardiolipin remodeling. However, it appears that cells compensate and ATP production is similar or higher than normal cells. Females heterozygous for the trait are unaffected. Sufferers of this condition have mitochondria that are abnormal. Cardiomyopathy and general weakness is common to these patients.
Sources: en.wikipedia.org
=== Economic policy === Ford's government cancelled the basic income pilot project. He opposes the laying off of government workers. He supports the use of attrition to eliminate government jobs that he believes are not needed. Ford believes in hiring independent auditors to audit government spending. Jay Goldberg of the Canadian Taxpayers Federation labelled Ford's spending excessive and noted Ontario's large debt increases under his government. In June 2019, Rod Phillips, who served as Minister of the Environment, Conservation and Parks, replaced Vic Fedeli as Ontario's finance minister. Andrea Khanjin was appointed as Parliamentary Assistant to the Minister of the Environment, Conservation and Parks in June 2018. Starting in January 2019, those who are working full-time and earning less than $30,000 a year would pay no provincial income tax, in the new LIFT program but minimum wage would be frozen at $14 per hour. They eliminated 3 legislative offices including the Environmental Commissioner of Ontario (ECO), child and youth advocate and French language services commissioner positions. The surtax on the highest earning Ontarians that would have generated about $275 million in revenue, was cancelled. The proposed French language university was cancelled as were three university satellite campuses. Fedeli served as minister until he was moved to economic development in June 2019 in a major cabinet shuffle.
== Controversy == Doctor's Data has proven controversial because of the four lawsuits that have been filed by people who say that the company victimized them by diagnosing them as having toxic metal poisoning based on their urinalysis tests, and then prescribing them chelation therapy. According to Patricia Callahan, the problem with these tests and the way they are interpreted is that, after administering a chelator to their patients, "Doctor's Data...compared those drug-provoked results to a reference range calculated for people who had never been given a chelation drug." In addition, they have faced considerable criticism from Stephen Barrett, who has described how provoked urine test reports are used to mislead patients. and has also written negatively about hair analysis in general, which he contends is "unscientific, economically wasteful, and probably illegal." Arthur Allen has also criticized the methodology of their urinalysis tests, saying that they "...present the results [from their urine analysis tests] in such a way that it almost guarantees a finding of "toxicity" for each child." In response to this criticism, Doctor's Data president Ted Lueken argued that "the technique can be valuable when used along with other tests and a doctor's knowledge of his patient." Doctor's Data later sued Barrett on June 18, 2010, accusing him of "...harm[ing] Doctor's Data by transmitting false, fraudulent and defamatory information about this company in a variety of ways" in his writings about the company.
=== Speech and sound creation === Sound synthesis, various methods of sound generation in audio electronics Wave field synthesis, a spatial audio rendering technique, characterized by creation of virtual acoustic environments Subtractive synthesis, a method of creating a sound by removing harmonics, characterised by the application of an audio filter to an audio signal Frequency modulation synthesis, a form of audio synthesis where the timbre of a simple waveform is changed by frequency modulating it with a modulating frequency that is also in the audio range Speech synthesis, the artificial production of human speech
Best opium 1/2 dr., dissolve it in about 2 tbsp [30 mL] of boiling water; then add benzoic acid 1/2 dr.; oil of anise 1/2 a fluid dr.; clarified honey 1 oz.; camphor gum 1 scruple; alcohol, 76 percent, 11 fluid ozs.; distilled water 4-1/2 fluid ozs.; macerate, (keep warm,) for two weeks. Dose – For children, 5 to 20 drops, adults, 1 to 2 tea-spoons. A dram (dr.) is about 1.8 grams, a modern teaspoon is 5 mL, and a scruple is 1⁄4 teaspoon.
Biden said he intended to eliminate some explicit roles assumed by George W. Bush's vice president, Dick Cheney, and did not intend to emulate any previous vice presidency. He was sworn in on January 20, 2009. He was the first vice president from Delaware and the first Roman Catholic vice president. Members of the Obama administration said Biden's role in the White House was to be a contrarian and force others to defend their positions. White House chief of staff Rahm Emanuel said Biden helped counter groupthink. The Bidens maintained a relaxed atmosphere at their official residence in Washington, often entertaining their grandchildren, and regularly returned to their home in Delaware. Biden oversaw infrastructure spending from the Obama stimulus package intended to help counteract the ongoing recession. Confronted with rising unemployment through July 2009, Biden acknowledged that the administration had "misread how bad the economy was", but maintained confidence the stimulus package would create many more jobs once the pace of expenditures picked up. When he completed that role in February 2011, he said the number of fraud incidents with stimulus monies had been less than one percent. Biden's off-message response to a question in April 2009, during the beginning of the swine flu outbreak, led to a swift retraction by the White House. The remark revived Biden's reputation for gaffes. A hot mic picked up Biden telling Obama that his signing the Patient Protection and Affordable Care Act was "a big fucking deal" on March 23, 2010.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.